Evidence map›Paper›PMID 42404632›Full record

ArticleMaterials today. Bio2026

Cantharidin-manganese based cocktail nanoplatform Co-activating ferroptosis and STING for enhanced HCC immunotherapy.

Shengmei Wang, Mengtian Ma, Qiuyan Guo, Guiming Deng, Xinhua Xia, Jianyu Li, Xueqing Tao, Dong Zhong, Kun Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shengmei WangDepartment of Radiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China.
Mengtian MaDepartment of Radiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China.
Qiuyan GuoSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
Guiming DengThe Second Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410005, China.
Xinhua XiaSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
Jianyu LiDepartment of Radiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China.
Xueqing TaoDepartment of Radiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China.
Dong ZhongSchool of Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
Kun ZhangDepartment of Radiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is often identified during its advanced phases, where therapeutic choices are constrained and patient prognosis is generally poor, creating a critical need for innovative treatment approaches. Despite the promise of immunotherapy, its efficacy is frequently constrained by the immunosuppressive tumor microenvironment (TME). To address this, we developed a multifunctional nanoplatform (CTD/MM@BSA) via a facile "one-pot" method, co-delivering the chemotherapeutic agent cantharidin (CTD) and manganese ions (Mn

Indexed as

CantharidincGAS-STING pathwayFerroptosisImmuno-ferroptosis synergistic therapyNanoparticles

Identifiers

PMID42404632
PMCPMC13332119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.